Lumigan, Travatan Statistically, Not Clinically, Superior To Timolol, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Allergan’s Lumigan (bimatoprost) and Alcon’s Travatan (travoprost) demonstrated statistically, but not clinically, significant improvement over timolol in lowering intraocular pressure, FDA concluded in NDA review documents for the two agents.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class